Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.

CONCLUSIONS: This study found that in current practice, physicians seem to be reluctant to prescribe injectable agents for patients with uncontrolled T2DM despite combination OAD therapy. Despite higher treatment persistence among patients adding a third OAD, this persistence did not translate into better glycemic control and may not necessarily be a long-term cost-saving solution. These data indicate a need for more evidence-based and patient-centered treatment decisions for patients unable to achieve and maintain glycemic targets on multiple OADs. PMID: 24761822 [PubMed - in process]
Source: Journal of Managed Care Pharmacy - Category: Drugs & Pharmacology Tags: J Manag Care Pharm Source Type: research